Interestingly, in parallel to changes in the epidemiology of GEP-NET, there have been substantial advances in treatment, such as the use of peptide receptor radiotherapy, and more recently, antiangiogenic agents (bevacizumab, everolimus, sunitinib), which have echoed on the prognosis of many patients with this disease. As shown by the results of the RADIANT trials, with the advent of targeted therapies, we may be on the verge of a paradigm shift in the treatment of advanced GEP-NETs.
The Spanish Group of Neuroendocrine Tumors (GETNE), aware of the interest this disease has raised due to its increasing incidence and significant advances in treatment, considered it would be of relevance to publish the contents from the"V GETNE Symposium on GEPNETs" held in September 2009 in the city of Madrid (Spain) . In this Special Issue, the updated contents of this symposium are reported. The purpose is to provide a general overview of the current state of knowledge of GEPNETs regarding diagnosis and innovations in therapy.
